DRREDDY - Dr. Reddy's Laboratories Limited
NSE
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Hyderabad,
India
Type: Equity
DRREDDY price evolution
DRREDDY
| (in millions $) | 29 Sep 2022 | 29 Jun 2022 | 30 Mar 2022 | 30 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $9096 | $6297 | $14852 | $21976 |
| Short term investments | $18479 | $28324 | $29513 | $13224 |
| Net receivables | $80052 | $76955 | $71815 | $66007 |
| Inventory | $49042 | $51810 | $50884 | $49675 |
| Total current assets | $175606 | $179708 | $181856 | $166829 |
| Long term investments | $6107 | $5214 | $7986 | $6491 |
| Property, plant & equipment | $63817 | $63826 | $62169 | $62971 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $290974 | $295975 | $292827 | $282499 |
| Current liabilities | ||||
| Accounts payable | $22778 | $25052 | $15971 | $24492 |
| Deferred revenue | ||||
| Short long term debt | $3800 | $3800 | ||
| Total current liabilities | $80031 | $90791 | $94015 | $83654 |
| Long term debt | $3800 | $3800 | ||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $84749 | $95586 | $102300 | $92483 |
| Shareholders' equity | ||||
| Retained earnings | $194492 | $188343 | $176467 | $175896 |
| Other shareholder equity | $2998 | $3437 | $5549 | $5643 |
| Total shareholder equity | $206225 | $200389 | $190527 | $190016 |
| (in millions $) | 30 Mar 2022 | 30 Mar 2021 | 30 Mar 2020 | 30 Mar 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $14852 | $14829 | $2053 | $2228 |
| Short term investments | $29513 | $19744 | $23687 | $22529 |
| Net receivables | $71815 | $54456 | $57309 | $45632 |
| Inventory | $50884 | $45412 | $35066 | $33579 |
| Total current assets | $181856 | $148249 | $130370 | $114501 |
| Long term investments | $7986 | $8333 | $3091 | $3342 |
| Property, plant & equipment | $62169 | $57111 | $52332 | $54088 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $292827 | $265491 | $232241 | $225427 |
| Current liabilities | ||||
| Accounts payable | $15971 | $12696 | $10745 | $10296 |
| Deferred revenue | ||||
| Short long term debt | $3783 | $4199 | ||
| Total current liabilities | $94015 | $83391 | $72814 | $59700 |
| Long term debt | $3800 | $3800 | $21448 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $102300 | $92429 | $77253 | $85230 |
| Shareholders' equity | ||||
| Retained earnings | $176467 | $157349 | $144247 | $128646 |
| Other shareholder equity | $5549 | $7961 | $2421 | $3045 |
| Total shareholder equity | $190527 | $173062 | $154988 | $140197 |
| (in millions $) | 29 Sep 2022 | 29 Jun 2022 | 30 Mar 2022 | 30 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $63057 | $52154 | $54368 | $53197 |
| Cost of revenue | $25810 | $26148 | $25625 | $24585 |
| Gross Profit | $37247 | $26006 | $28743 | $28612 |
| Operating activities | ||||
| Research & development | $4869 | $4325 | $4326 | $4159 |
| Selling, general & administrative | $16560 | $15493 | $16016 | $15411 |
| Total operating expenses | $46816 | $45601 | $45609 | $43940 |
| Operating income | $16241 | $6553 | $8759 | $9257 |
| Income from continuing operations | ||||
| EBIT | $16241 | $6553 | $8759 | $9257 |
| Income tax expense | $4983 | $2779 | $1608 | $2644 |
| Interest expense | -$309 | -$347 | -$316 | -$215 |
| Net income | ||||
| Net income | $11128 | $11876 | $875 | $7065 |
| Income (for common shares) | $11128 | $11876 | $875 | $7065 |
| (in millions $) | 30 Mar 2022 | 30 Mar 2021 | 30 Mar 2020 | 30 Mar 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $214391 | $189722 | $174600 | $153851 |
| Cost of revenue | $100551 | $86645 | $80591 | $70421 |
| Gross Profit | $113840 | $103077 | $94009 | $83430 |
| Operating activities | ||||
| Research & development | $17482 | $16541 | $15410 | $15607 |
| Selling, general & administrative | $62081 | $54590 | $50129 | $48680 |
| Total operating expenses | $178472 | $156752 | $145287 | $134176 |
| Operating income | $35919 | $32970 | $29313 | $19675 |
| Income from continuing operations | ||||
| EBIT | $35919 | $32970 | $29313 | $19675 |
| Income tax expense | $8730 | $9175 | -$1466 | $3648 |
| Interest expense | -$958 | -$970 | -$983 | -$889 |
| Net income | ||||
| Net income | $23568 | $17238 | $19498 | $18795 |
| Income (for common shares) | $23568 | $17238 | $19498 | $18795 |
| (in millions $) | 29 Sep 2022 | 29 Jun 2022 | 30 Mar 2022 | 30 Dec 2021 |
|---|---|---|---|---|
| Net income | $11128 | $11876 | $875 | $7065 |
| Operating activities | ||||
| Depreciation | $3126 | $3050 | $2958 | $2976 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $9281 | $6655 | $9119 | $17331 |
| Investing activities | ||||
| Capital expenditures | -$2511 | -$3305 | -$3741 | -$4138 |
| Investments | $8882 | $3505 | -$18015 | $1415 |
| Total cash flows from investing | $5733 | -$4923 | -$21988 | -$2761 |
| Financing activities | ||||
| Dividends paid | -$4979 | |||
| Sale and purchase of stock | ||||
| Net borrowings | -$7071 | -$10290 | $5402 | -$2197 |
| Total cash flows from financing | -$12346 | -$10800 | $5097 | -$2568 |
| Effect of exchange rate | $128 | $513 | $648 | -$6 |
| Change in cash and equivalents | $2796 | -$8555 | -$7124 | $11996 |
| (in millions $) | 30 Mar 2022 | 30 Mar 2021 | 30 Mar 2020 | 30 Mar 2019 |
|---|---|---|---|---|
| Net income | $23568 | $17238 | $19498 | $18795 |
| Operating activities | ||||
| Depreciation | $11824 | $12796 | $12472 | $12190 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $28108 | $35703 | $29841 | $28704 |
| Investing activities | ||||
| Capital expenditures | -$14660 | -$9741 | -$4846 | -$6955 |
| Investments | -$11201 | $4110 | -$214 | -$2282 |
| Total cash flows from investing | -$26387 | -$22660 | -$4923 | -$7727 |
| Financing activities | ||||
| Dividends paid | -$4146 | -$4147 | -$3314 | -$3320 |
| Sale and purchase of stock | ||||
| Net borrowings | $2735 | $6094 | -$19165 | -$15182 |
| Total cash flows from financing | -$2422 | -$298 | -$25159 | -$21326 |
| Effect of exchange rate | $733 | $113 | -$25 | $35 |
| Change in cash and equivalents | $32 | $12858 | -$266 | -$314 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $222.78B |
|---|---|
| EBITDA | $52.92B |
| EBIT | $40.81B |
| Net Income | $30.94B |
| Revenue Q/Q | 9.41% |
| Revenue Y/Y | 9.52% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | 10.65% |
| ROE | 15.72% |
| Debt/Equity | 0.54 |
|---|---|
| Net debt/EBITDA | 1.43 |
| Current ratio | 2.19 |
| Quick ratio | 1.58 |